Outlook Therapeutics (OTLK) CEO Robert Jahr Buys 151,515 Shares

What Happened

• Robert Charles Jahr, CEO of Outlook Therapeutics (OTLK), purchased 151,515 shares of common stock and received 151,515 accompanying warrants in the company's underwritten public offering on August 14, 2026. The combined public offering price was $0.99 per share-plus-warrant, implying a total outlay of about $150,000.
• This was a purchase (insider buy), which many investors view as a more informative signal than routine sales. The warrants are derivative securities issued alongside the shares.

Key Details

• Transaction date: August 14, 2026; Filing date (Form 4): August 14, 2026.
• Price: $0.99 per unit (one share + one warrant); total consideration ≈ $149,999.85 (~$150k).
• Securities acquired: 151,515 common shares and 151,515 warrants (warrants recorded as derivative holdings).
• Warrants: exercisable immediately upon issuance; expire five years later on August 14, 2031 (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported same day (no late filing indicated in the supplied data).

Context

• The purchase was made through the issuer's public offering (not a market open-market purchase), with the warrants issued as part of the unit. Warrants give the holder the right to buy additional shares under their terms; these were immediately exercisable but will expire in five years.
• As with all insider filings, this is factual disclosure of ownership change only and does not explain the insider's motives. Purchases by executives are often watched by retail investors as a potential sign of confidence, but they should be considered alongside other company fundamentals and news.